Pharmaresearch Makes Strategic Investment in Drug Development Company Conext
Securing Commercialization Rights for 'CNT201'
On March 3, Pharmaresearch announced that it has signed a strategic investment agreement with the bio-venture company Conext, establishing a mid- to long-term partnership.
Conext is a venture company developing biopharmaceuticals based on protein recombination research and development as well as process technology. Previously, Pharmaresearch signed a licensing-in agreement regarding 'CNT201,' Conext's core pipeline and a new drug candidate.
CNT201 is a biopharmaceutical with the potential to expand into a wide range of indications, from aesthetic areas such as cellulite, Dupuytren's contracture, and Peyronie's disease, to therapeutic applications. Recently, Phase 1 clinical trials were completed with the U.S. Food and Drug Administration (FDA), and Phase 2 trials are currently underway.
Through this investment, Pharmaresearch has secured broad commercialization rights for 'CNT201.' The company also plans to actively pursue business collaborations based on Conext's technology. In addition, Pharmaresearch aims to promote an open innovation model for the development of various biopharmaceuticals.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Pharmaresearch representative stated, "With this investment as a catalyst, the two companies will collaborate even more closely to accelerate the commercial success of CNT201 and the development of next-generation pipelines."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.